| References |
1. Wan Y, Wu N, Song L, Wang X, Liu Z, Yuan W, Gan J. Levodopa/Benserazide Loaded Microspheres Alleviate L-dopa Induced Dyskinesia through Preventing the Over-Expression of D1R/Shp-2/ERK1/2 Signaling Pathway in a Rat Model of Parkinson's Disease. Front Aging Neurosci. 2017 Oct 18;9:331. doi: 10.3389/fnagi.2017.00331. eCollection 2017. PubMed PMID: 29093677; PubMed Central PMCID: PMC5651254. 2. Wollmer E, Klein S. Development and Validation of a Robust and Efficient HPLC Method for the Simultaneous Quantification of Levodopa, Carbidopa, Benserazide and Entacapone in Complex Matrices. J Pharm Pharm Sci. 2017;20(0):258-269. doi: 10.18433/J3K923. PubMed PMID: 28810948. 3. Pellegrini C, Antonioli L, Colucci R, Tirotta E, Gentile D, Ippolito C, Segnani C, Levandis G, Cerri S, Blandini F, Barocelli E, Ballabeni V, Bernardini N, Blandizzi C, Fornai M. Effects of L-DOPA/benserazide co-treatment on colonic excitatory cholinergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration. Neuropharmacology. 2017 Sep 1;123:22-33. doi: 10.1016/j.neuropharm.2017.05.016. Epub 2017 May 17. PubMed PMID: 28526609. 4. Li W, Zheng M, Wu S, Gao S, Yang M, Li Z, Min Q, Sun W, Chen L, Xiang G, Li H. Benserazide, a dopadecarboxylase inhibitor, suppresses tumor growth by targeting hexokinase 2. J Exp Clin Cancer Res. 2017 Apr 20;36(1):58. doi: 10.1186/s13046-017-0530-4. PubMed PMID: 28427443; PubMed Central PMCID: PMC5399312. |
